GSK Exits Consumer Health With Haleon Launch
The global market leader in consumer health is now Haleon following its separation from GSK after more than two years of planning.
You may also be interested in...
The UK major has teamed up with the US biotech to develop the latter’s HER-2 targeted antibody-drug conjugate, a couple of years after the approval of Blenrep, in what is becoming an increasingly competitive space.
Andrew Loucks moves to Sanofi from helm of consumer health and technology firm Sensory Cloud as business navigates gaining US OTC heartburn market share for Zantac brand, which it relaunched with famotidine replacing ranitidine as the active ingredient.
A better than expected first-half performance has put Haleon on a sure footing for the rest of the year following its recent demerger from GSK.